Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 1
Submit an article Journal homepage
75
Views
0
CrossRef citations to date
0
Altmetric
Reviews

Resistant gastroenteropancreatic neuroendocrine tumors: a definition and guideline to medical and surgical management

Catherine H. Davisa Division of Surgical Oncology, Baylor University Medical Center, Dallas, Texas, USA;b Texas A&M University School of Medicine, Dallas, Texas, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0976-8054
, MD, MPHORCID Icon,
Amanda M. Lairdc Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA;d Rutgers Robert Wood Johnson University Medical School, New Brunswick, New Jersey, USA
, MD &
Steven K. Libuttic Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA;d Rutgers Robert Wood Johnson University Medical School, New Brunswick, New Jersey, USA
, MD
Pages 104-110 | Received 22 Aug 2023, Accepted 07 Nov 2023, Published online: 20 Dec 2023

  • Pearse AG. The APUD concept and hormone production. Clin Endocrinol Metab. 1980;9(2):211–222. doi:10.1016/s0300-595x(80)80030-2.
  • Zandee WT, Kamp K, van Adrichem RC, Feelders RA, de Herder WW. Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. Endocr Relat Cancer. 2017;24(7):R261–R274. doi:10.1530/ERC-16-0538.
  • Kyriakopoulos G, Mavroeidi V, Chatzellis E, Kaltsas GA, Alexandraki KI. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med. 2018;6(12):252–252. doi:10.21037/atm.2018.06.27.
  • Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–918. doi:10.1677/ERC-10-0152.
  • Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. doi:10.1001/jamaoncol.2017.0589.
  • Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–860. doi:10.1016/j.annonc.2020.03.304.
  • Rindi G, Inzani F. Neuroendocrine neoplasm update: toward universal nomenclature. Endocr Relat Cancer. 2020;27(6):R211–R218. doi:10.1530/ERC-20-0036.
  • Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12(2):153–172. doi:10.1016/s0960-7404(03)00034-3.
  • Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–1492. doi:10.1053/j.gastro.2008.05.047.
  • Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105(3):212–244. doi:10.1159/000471879.
  • Gabriel S, Garrigue P, Dahan L, et al. Prospective evaluation of (68) Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. Clin Endocrinol (Oxf). 2018;89(2):155–163. doi:10.1111/cen.13745.
  • Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018;59(1):66–74. doi:10.2967/jnumed.117.202275.
  • Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol. 2016;34(6):588–596. doi:10.1200/JCO.2015.64.0987.
  • Ma ZY, Gong YF, Zhuang HK, et al. Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management. World J Gastroenterol. 2020;26(19):2305–2322. doi:10.3748/wjg.v26.i19.2305.
  • Philips P, Kooby DA, Maithel S, et al. Grading using Ki-67 index and mitotic rate increases the prognostic accuracy of pancreatic neuroendocrine tumors. Pancreas. 2018;47(3):326–331. doi:10.1097/MPA.0000000000000990.
  • Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1–33. doi:10.1097/MPA.0000000000001454.
  • Jung JG, Lee KT, Woo YS, et al. Behavior of small, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs). Medicine (Baltimore). 2015;94(26):e983. doi:10.1097/MD.0000000000000983.
  • Sallinen VJ, Le Large TYS, Tieftrunk E, et al. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors—a multi-institutional study. HPB (Oxford). 2018;20(3):251–259. doi:10.1016/j.hpb.2017.08.034.
  • Triponez F, Sadowski SM, Pattou F, et al. Long-term follow-up of MEN1 patients who do not have initial surgery for small ≤2 cm nonfunctioning pancreatic neuroendocrine tumors, an AFCE and GTE study: Association Francophone de Chirurgie Endocrinienne & Groupe d‘Etude des Tumeurs Endocrines. Ann Surg. 2018;268(1):158–164. doi:10.1097/SLA.0000000000002191.
  • Barenboim A, Lahat G, Nachmany I, et al. Resection versus observation of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors. J Gastrointest Surg. 2020;24(6):1366–1374. doi:10.1007/s11605-019-04285-y.
  • Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: a clinical snapshot. World J Gastrointest Surg. 2021;13(3):231–255. doi:10.4240/wjgs.v13.i3.231.
  • Kalshetty A, Ramaswamy A, Ostwal V, Basu S. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting. Nucl Med Commun. 2018;39(12):1143–1149. doi:10.1097/MNM.0000000000000926.
  • Antonuzzo L, Del Re M, Barucca V, et al. Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors. Cancer Treat Rev. 2017;57:28–35. doi:10.1016/j.ctrv.2017.05.001.
  • Luley K, Gebauer J, Gebauer N, et al. Gastroenteropancreatic neuroendocrine neoplasms—heterogeneity, management and perspectives of treatment and research. Internist (Berl). 2020;61(8):875–890. doi:10.1007/s00108-020-00832-x.
  • Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(16):1556–1557. doi:10.1056/NEJMc1409757.
  • Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–188. doi:10.1111/j.1365-2036.2009.04174.x.
  • Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–4663. doi:10.1200/JCO.2009.22.8510.
  • Zanini S, Renzi S, Giovinazzo F, Bermano G. mTOR pathway in gastroenteropancreatic neuroendocrine tumor (carcinoids). Front Endocrinol (Lausanne). 2020;11:562505. doi:10.3389/fendo.2020.562505.
  • Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Therap Adv Gastroenterol. 2017;10(1):132–141. doi:10.1177/1756283X16674660.
  • Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968–977. doi:10.1016/S0140-6736(15)00817-X.
  • Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–2012. doi:10.1016/S0140-6736(11)61742-X.
  • Fazio N, Buzzoni R, Baudin E, et al. A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours. Anticancer Res. 2016;36(2):713–719.
  • Beyens M, Vandamme T, Peeters M, Van Camp G, Op de Beeck K. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2019;26(3):R109–R130. doi:10.1530/ERC-18-0420.
  • Fazio N, Cella CA, Del Re M, et al. Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors. Expert Opin Drug Metab Toxicol. 2019;15(12):993–1004. doi:10.1080/17425255.2019.1700951.
  • Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513. doi:10.1056/NEJMoa1003825.
  • Daskalakis K, Tsoli M, Angelousi A, et al. Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms. Endocr Connect. 2019;8(6):641–653. doi:10.1530/EC-19-0134.
  • Hobday TJ, Qin R, Reidy-Lagunes D, et al. Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol. 2015;33(14):1551–1556. doi:10.1200/JCO.2014.56.2082.
  • Tsoli M, Alexandraki K, Xanthopoulos C, Kassi E, Kaltsas G. Medical treatment of gastrointestinal neuroendocrine neoplasms. Horm Metab Res. 2020;52(8):614–620. doi:10.1055/a-1110-7251.
  • Chatzellis E, Angelousi A, Daskalakis K, et al. Activity and safety of standard and prolonged capecitabine/temozolomide administration in patients with advanced neuroendocrine neoplasms. Neuroendocrinology. 2019;109(4):333–345. doi:10.1159/000500135.
  • Brabander T, Teunissen JJ, Van Eijck CH, et al. Peptide receptor radionuclide therapy of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2016;30(1):103–114. doi:10.1016/j.beem.2015.10.005.
  • Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135. doi:10.1056/NEJMoa1607427.
  • Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617–4624. doi:10.1158/1078-0432.CCR-16-2743.
  • Starr JS, Sonbol MB, Hobday TJ, Sharma A, Kendi AT, Halfdanarson TR. Peptide receptor radionuclide therapy for the treatment of pancreatic neuroendocrine tumors: recent insights. Onco Targets Ther. 2020;13:3545–3555. doi:10.2147/OTT.S202867.
  • Sansovini M, Severi S, Ianniello A, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with. Eur J Nucl Med Mol Imaging. 2017;44(3):490–499. doi:10.1007/s00259-016-3533-z.
  • Cella D, Beaumont JL, Hudgens S, et al. Relationship between symptoms and health-related quality-of-life benefits in patients with carcinoid syndrome: post hoc analyses from TELESTAR. Clin Ther. 2018;40(12):2006–2020.e2. doi:10.1016/j.clinthera.2018.10.008.
  • Falciani C, Brunetti J, Pagliuca C, et al. Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents. ChemMedChem. 2010;5(4):567–574. doi:10.1002/cmdc.200900527.
  • Libutti SA, Sosa JA, Kunz P, et al. Phase 2 study of fosbretabulin tromethamine (CA4P) for the treatment of well-differentiated, low-to-intermediate-grade unresectable, recurrent or metastatic pancreatic or gastrointestinal neuroendocrine tumors/carcinoid with elevated biomarkers. Abstracts Presented at the 8th Annual Meeting of the North American NeuroEndocrine Tumor Society, October 14–18, 2015, Austin, TX. doi:10.1097/MPA.0000000000000615.
  • Scott AT, Breheny PJ, Keck KJ, et al. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165(1):166–175. doi:10.1016/j.surg.2018.04.070.
  • Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163(1):218–225. doi:10.1016/j.surg.2017.05.030.
  • Maxwell JE, Sherman SK, O’Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy? Surgery. 2016;159(1):320–333. doi:10.1016/j.surg.2015.05.040.
  • Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169(1):36–43. discussion 42-3. doi:10.1016/s0002-9610(99)80107-x.
  • Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37. doi:10.1016/S1072-7515(03)00230-8.
  • De Jong MC, Farnell MB, Sclabas G, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann Surg. 2010;252(1):142–148. doi:10.1097/SLA.0b013e3181dbb7a7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.